Atavistik Bio is a biotechnology company that focuses on the discovery and development of novel therapies for metabolic diseases and cancer.
Atavistik Bio has raised $40.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2023.
Atavistik Bio's investors include Lux Capital, The Column Group, Nextech Invest.
Atavistik Bio is headquartered in Cambridge, United States.
Atavistik Bio is a biotechnology company that focuses on the discovery and development of novel therapies for metabolic diseases and cancer.
Atavistik Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Atavistik Bio — Funding & Investors." VCBacked, December 19, 2023, https://www.vcbacked.co/company/atavistik-bio-cambridge-2. Accessed October 21, 2026.
VCBacked. (2023). Atavistik Bio — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/atavistik-bio-cambridge-2
{{cite web |title=Atavistik Bio — Funding & Investors |url=https://www.vcbacked.co/company/atavistik-bio-cambridge-2 |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated